The appointment of Dr. Elias Theodorou, an expert in relevant research fields, to the board of Defence Therapeutics Inc. is likely to positively impact the company's strategic initiatives in developing its core products. This could lead to increased investor confidence and a potential short-term positive impact on the stock price.